T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens First FDA-cleared test to identify sepsis-causing bacteria direct from whole blood Cuts time to diagnosis from day

T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens

First FDA-cleared test to identify sepsis-causing bacteria direct from whole blood

Cuts time to diagnosis from days to hours, allowing greater certainty and new protocols for deadly infections in hospital setting

Company to host conference call to discuss T2Bacteria and provide financial guidance at 8:30 a.m. ET on Tuesday, May 29, 2018

LEXINGTON, Mass., May 29, 2018 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of

innovative diagnostic products for critical unmet needs in healthcare, today announced that it has received market clearance from the U.S. Food and Drug Administration (FDA) for the

T2Bacteria Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. The T2Bacteria Panel, for the first time,

provides sensitive detection of specific sepsis-causing bacterial pathogens directly from a whole blood specimen in approximately 5 hours. This was more than 2.5 days faster than blood culture-dependent tests as demonstrated in the over 1,400

patient pivotal trial conducted at 11 hospitals in the United States. All other FDA-cleared diagnostic tests that detect bacteria in blood require a positive blood culture sample prior to bacterial species

specific identification, which typically delays results by one to five days. For patients at risk of sepsis, rapid targeted treatment based on the identification of causative pathogens is critical because it is estimated that every hour of speeding

up the time to targeted therapy decreases patient mortality by nearly 8%.

The results from the T2Bacteria pivotal clinical trial were impressive, demonstrating excellent performance and

advantages over blood culture, said Minh-Hong Nguyen, MD, director, Antimicrobial Management Program and director, Transplant Infectious Diseases, UPMC. T2Bacteria s detection of bloodstream infections and fast species

identification at high sensitivity will expedite life-saving interventions such as the targeting of therapy within hours of blood draw.

T2Bacteria Panel, like the previously FDA-cleared T2Candida Panel, runs on the Company s proprietary,

FDA-cleared T2Dx Instrument. The FDA-cleared T2Bacteria Panel identifies five of the most common and deadly

sepsis-causing species of bacteria: Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.

Bacterial and fungal bloodstream infections are a leading cause of sepsis, a life-threatening illness that

affects 1.6 million U.S. patients each year, resulting in over 250,000 deaths or almost 50% of all deaths of U.S. hospitalized patients. Studies have shown that the mortality rate for bloodstream infections can be reduced significantly with

appropriate targeted therapy within 12 hours.

The FDA s market clearance of the T2Bacteria Panel is a significant milestone for our company,

but more importantly, for millions of patients at risk of sepsis from bloodstream infections, said John McDonough, president and chief executive officer of T2 Biosystems. This breakthrough technology provides potentially life-saving

answers for patients and economic savings to hospitals that bear the enormous burden of sepsis-related care and mortality.

Management will host a conference call today with the investment community at 8:30 a.m. Eastern Time to discuss key T2Bacteria commercial

launch activities in more detail and provide updated 2018 full-year financial guidance. Interested parties may access the live call via telephone by dialing

1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via

T2 Biosystems website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events &

Presentations section of the website.

About Bloodstream Infections

Treating bloodstream infections earlier may prevent progression to sepsis, one of the leading causes of death in the U.S. and the most expensive

hospital-treated condition, with costs exceeding $27 billion. Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined and is the most prevalent and costly cause of hospital readmissions. The pathogens that

cause sepsis infections are difficult to detect and can be deadly even at very small concentrations in the bloodstream. With sepsis, one hour of delayed treatment increases mortality risk by nearly 8%. The T2Bacteria Panel uses magnetic resonance

technology to help detect the presence of five clinically relevant species of bacteria directly from a patient s blood sample in approximately five hours, versus one to five days or more with current diagnostic methods, potentially

enabling more rapid treatment that may prevent the progression of a bloodstream infection to sepsis.

About T2 Biosystems:

T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare,

improves patient care and reduces the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems products include the T2Dx Instrument, T2Candida Panel and T2Bacteria Panel and are powered by the

proprietary T2 Magnetic Resonance (T2MR ) technology. T2 Biosystems has an active pipeline of future products, including detection of additional species and antibiotic resistance markers of

sepsis pathogens and tests for Lyme disease. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in

this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding product pipeline, anticipated product benefits, goals and strategic priorities,

product expansion or opportunities, growth expectations or targets and FDA clearance, as well as statements that

include the words expect, intend, plan, believe, project, forecast, estimate, may,

should, anticipate and similar statements of a future or forward-looking nature. These forward-looking statements are based on management s current expectations. These statements are neither promises nor guarantees, but

involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the

forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to

market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or

(i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at

all; or (iv) the factors discussed under Item 1A. Risk Factors in the Company s Annual Report on Form 10-K for the year-ended December 31, 2017, filed with the U.S. Securities and

Exchange Commission (SEC) on March 19, 2018, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking

statements made in this press release. Any such forward-looking statements represent management s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future,

unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, one should not assume that the Company s silence over time means that actual events are bearing out as expressed or implied

in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company s views as of any date subsequent to the date of this press release.

Tom Langford, Feinstein Kean Healthcare

Matthew Clawson, W2O Group